The EXTENT Study: Results from an International Expert Delphi Consensus to define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn&apos;s Disease

Inflammatory Bowel Disease

Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey

J Crohns Colitis

Moreira PL, Dignass A, Estevinho MM, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Dotan I, Jairath V, Magro F, International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)

doi: 10.1093/ecco-jcc/jjaf178

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

RECOMMENDED

Inflammatory Bowel Disease

Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey

★ 3 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

J Crohns Colitis

Fiorino G, Fidalgo C, Adamina M, Barreiro-de Acosta M, Ali MP, Bortlik M, Burisch J, Dignass A, Drobne D, Faiz O, Ferrante M, Fierens L, Godny L, Gojdicova A, Iacucci M, Jӓghult S, Karmiris K, Kirchgesner J, Restellini S, Rosini F, Shouval D, Yanai H, Zagórowicz E, Walsh A, European Crohn’s Colitis Organisation

doi: 10.1093/ecco-jcc/jjaf105

Inflammatory Bowel Disease

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

J Crohns Colitis

Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK

doi: 10.1093/ecco-jcc/jjaf213

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

J Crohns Colitis

Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I

doi: 10.1093/ecco-jcc/jjaf138

Inflammatory Bowel Disease

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study

Am J Gastroenterol

Lee SD, Vermeire S, Ungaro R, Vadhariya A, Durand F, Morris N, Yu G, Fisher DA, Traxler K, Long M

doi: 10.14309/ajg.0000000000003410

Inflammatory Bowel Disease

Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study

Clin Gastroenterol Hepatol

Panaccione R, Regueiro M, Lee SD, Atreya R, Pedersen G, Broide E, Rodriguez C, van Bodegraven AA, Dubcenco E, Lacerda AP, Feng T, Geng Z, Wang T, van Haaren S, Anyanwu SI, Panés J

doi: 10.1016/j.cgh.2025.07.028

Inflammatory Bowel Disease

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease

Inflamm Bowel Dis

Fumery M, Savoye G, Sarter H, Dupont-Lucas C, Bertrand V, Wils P, Richard N, Guillon N, Gower-Rousseau C, Turck D, Ley D, Leroyer A, EPIMAD group

doi: 10.1093/ibd/izaf133

Inflammatory Bowel Disease

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Gastroenterology

Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G

doi: 10.1053/j.gastro.2025.02.033

Related content

Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study

Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study